ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

PR Newswire

LOS ANGELES, April 9, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQ: FGEN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. FibroGen issued a statement on April 6, 2021, providing “clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (‘CKD’).” The Company stated that its safety analysis “included post-hoc changes to the stratification factors.” FibroGen disclosed that based on analyses using the pre-specified stratification factors, the Company “cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa.” Based on this news, shares of FibroGen dropped sharply.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm 
Brian Schall, Esq. 
310-301-3335
[email protected] 
www.schallfirm.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ongoing-investigation-alert-the-schall-law-firm-announces-it-is-investigating-claims-against-fibrogen-inc-and-encourages-investors-with-losses-of-100-000-to-contact-the-firm-301265951.html

SOURCE The Schall Law Firm

RYU Apparel Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

PR Newswire

VANCOUVER, BC, April 9, 2021 /PRNewswire/ – RYU Apparel Inc. (TSXV: RYU) (OTC: RYPPF) (FWB: RYAA), an award winning urban athletic apparel and accessories brand will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, April 10 at 7 p.m. EST in the United States. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. EST in 73M homes.

To view the interview segment, please visit: https://youtu.be/S37xDERmoSs.

“The RedChip Money Report” delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About RYU Apparel

RYU Apparel (TSXV: RYU, OTCQB: RYPPF), or Respect Your Universe, is an award winning urban athletic apparel and accessories brand engineered for the fitness, performance and lifestyle of the athletic man and woman. Designed without compromise for fit, comfort, and durability, RYU exists to facilitate optimal human performance. For more information, please visit the RYU website at: http://ryu.com.

Forward Looking Statements Disclaimer

Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange Inc.) accepts responsibility for the adequacy or accuracy of this press release.

This news release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of RYU, such as statements the launching a golf apparel division, booming golf industry, future sales, continued appointment from Rob Blair, expressed in the forward-looking information, including: (i) adverse market conditions, including conditions arising as a result of the COVID-19 pandemic or otherwise; (ii) an inability to renew the RYU brand, implement strategic objectives and regain profitability; (iii) failing to meet target revenue projections as anticipated; (iv) failing to enter into the anticipated consulting arrangement and (v) the inability to complete the planned re-opening of the its store or the piloting of the “RYU Studio” concept. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking statements are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, RYU does not intend to update these forward-looking statements.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ryu-apparel-inc-interview-to-air-on-bloomberg-television-us-on-the-redchip-money-report-301265997.html

SOURCE RYU Apparel Inc.

Correction: Alpine Banks of Colorado Maintains Common Shareholder Dividend

Glenwood Springs, Colo., April 09, 2021 (GLOBE NEWSWIRE) — Alpine Banks of Colorado (OTCQX: ALPIB) announced today that a quarterly cash dividend of $0.16 per Class B nonvoting common share will be paid on April 26, 2021, to shareholders of record at the close of business on April 19, 2021. Per the Articles of Incorporation, dividends on the Class B nonvoting common stock shall be declared by the Board of Directors equal to one-one-hundred-fiftieth (1/150th) of the amount per share declared by the Board of Directors for each share of Class A voting common stock. Alpine Banks of Colorado Class B nonvoting common shares are publicly traded on the OTCQX® Best Market under the symbol “ALPIB”.

Additionally, a quarterly cash dividend of $24.00 per Class A voting common share will be paid on April 26, 2021, to shareholders of record at the close of business on April 19, 2021. Alpine Banks of Colorado Class A voting common shares are not publicly traded.

The dividend of $24.00 per Class A voting common share and $0.16 per Class B nonvoting common share is unchanged from the dividend paid in the previous quarter.


###

About Alpine Banks of Colorado

Alpine Banks of Colorado, through its wholly owned subsidiary Alpine Bank, is an employee-owned organization with over $5 billion in assets—founded in 1973 and headquartered in Glenwood Springs, Colorado. With 39 banking offices across Colorado, Alpine Bank employs more than 760 people and serves more than 160,000 customers with personal, business, wealth management*, mortgage and electronic banking services. Alpine Bank has a 5-star rating for financial strength by BauerFinancial, Inc., the nation’s leading bank rating firm. The 5-star rating is BauerFinancial’s highest rating for financial institutions. Learn more at www.alpinebank.com. Alpine Banks of Colorado trades Class B Nonvoting Common Stock under the symbol “ALPIB” on the OTCQX® Best Market.

 *Alpine Bank Wealth Management services are not FDIC insured, may lose value and are not guaranteed by the bank.



Eric Gardey
Alpine Banks of Colorado
(970) 384-3257
[email protected]

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas


PARIS AND CAMBRIDGE, MA – April 9, 2021 – Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones.

“We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population,”
said Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi. “We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions.”

Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body. The technology delivers mRNA cargos selectively to designated types of cells in the body, with initial applications targeting specific types of immune cells. The in vivo approach is designed to provide similar efficacy to current ex vivo (outside the body) approaches where immune cells are genetically modified to enhance their therapeutic properties (such as chimeric antigen receptor [CAR]-expressing T-cells), with the potential for improved safety, outpatient dosing, and repeat dosing. Currently, Tidal Therapeutics has ongoing pre-clinical programs including in vivo re-programming of T cells or other types of immune cells for cancer indications.

“Teaming up with Sanofi gives us the opportunity to further develop our unique platform and rapidly apply it to ultimately help patients across a range of diseases,” said Ulrik Nielsen, President and CEO, Tidal Therapeutics.

About Tidal Therapeutics

Tidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases. The company was seeded by Mission BioCapital, and joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures, and AbbVie Ventures.

 

About Sanofi

 

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

 

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

 

Sanofi, Empowering Life

 


Media Relations Contact

Sally Bain
Tel: +1 (781) 264-1091
[email protected]

 

 

 

Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine

 

Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco

 

IR main line:
Tel.: +33 (0)1 53 77 45 45
[email protected]
https://www.sanofi.com/en/investors/contact


 


Sanofi Forward-Looking Statements


This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions,  cost containment initiatives and subsequent changes thereto, and  the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

 

Attachment



Proactive news headlines including Alternus Energy, KWESST Micro Systems, Phyto Extractions and CytoDyn

Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

New York, April 09, 2021 (GLOBE NEWSWIRE) —

  • Alternus Energy Group PLC (NOTC:ALT) on pace to see a tenfold increase in its power capacity by the end of 2023 click here
  • Predictiv AI Inc (CVE: PAI) (OTCMKTS:INOTF) (FSE:71TA) installs ThermalPass scanners at Memorial Healthcare System facilities in south Broward County, Florida click here
  • American Manganese Inc (CVE:AMY) (OTCQB:AMYZF) (FRA:2AM) improves the manganese processing flowsheet for its US Defense Logistics Agency project click here
  • Hillcrest Petroleum Ltd (CSE:HEAT) (OTCMKTS:HLRTF) (FRA:7HI.F) rebranding as Hillcrest Energy Technologies as it transitions from fossil fuels to clean tech innovation and IP development click here
  • KWESST Micro Systems Inc (CVE:KWE) (OTCQB:KWEMF) upsizes brokered private placement to C$4M after it sees significant demand from investors click here
  • American Battery Metals Corporation (OTCQB:ABML) COO to speak at the US Energy Storage Association conference this month click here
  • ImagineAR Inc (CSE:IP) (OTCQB:IPNFF) technology ‘drafted’ by two motorsports organizations on day two of the Hype Sports Innovation Accelerator click here
  • Aurania Resources Ltd (CVE:ARU) (OTCMKTS:AUIAF) (FRA:20Q) finds black “pyrobitumen” through drilling at Kuri-Yawi target at Lost Cities- Cutucu project click here
  • CytoDyn Inc (OTCQB:CYDY) says its coronavirus long-haulers trial now fully enrolled faster than expected click here
  • Phyto Extractions Inc (CSE:XTRX)(FRA:D2EP) launches three new Shatter Products, adding to its product line in the burgeoning cannabis extracts market click here
  • BioSig Technologies Inc (NASDAQ:BSGM) accepts invitation to join the Alliance for Artificial Intelligence in Healthcare click here
  • Vuzix Corporation (NASDAQ:VUZI) announces online panel discussion to discuss key takeaways for successful deployment of augmented reality for enterprise customers click here

About Proactive

With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors.

Proactive’ s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally.

Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

•           Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.

•           We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate.

•           We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy.

•           Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting.

•           We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.

For more information on how Proactive can help you make a difference, email us at [email protected]


 



Healixa Inc. Provides Pharmacy Business Progress Updates

Emerald Organic Products Inc. (d/b/a Healixa Inc.) in Final Stages of Testing for its Proprietary Prescription Delivery Technology

Holbrook, New York, April 09, 2021 (GLOBE NEWSWIRE) — Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, “EMOR”, “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, is pleased to provide a progress update on the Company’s pharmacy business plan rollout subsequent to its recent acquisition of 5 Star Pharmacy LLC in Allen, Texas.

“The upcoming launch of the Company’s digital pharmacy application alongside our active acquisition strategy should fuel significant growth,” commented Ian Parker, CEO of Healixa. “We are pleased to provide an update on the previously announced pharmacy business plan rollout, as well as highlight some of the Company’s recent initiatives.”


Pharmacy Business Plan Rollout

  • The Company has begun integrating 5 Star Pharmacy LLC into its digital healthcare ecosystem;
  • The Company is in its final stages of testing its Rx last mile logistics application;
  • Upon completion of testing this quarter the Company’s digital pharmacy application will be launched nationally in strategic regional locations in and in phases, beginning with select metropolitan areas.


Advisory Board Build-Out

Following the Company’s February 24, 2021 announcement regarding its name change to Healixa and refined corporate vision for the future, there have been multiple noteworthy appointments to the Company’s Advisory Board:

The Company has also bolstered its team with the recent appointment Kealy Altman as Vice President of Marketing. 

“The Company is undergoing a massive transformation to become a formidable force in the healthtech space,” added Parker. “I look forward to providing additional updates to shareholders in the near future as we begin commercializing our  Rx  last mile logistics application.”

About Emerald Organic Products Inc.

Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.  

About Healixa Inc.

Healixa is a technology company with assets in both healthtech and fintech.  Healixa marries code and care to create exceptional experiences in healthtech.  The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.

Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 



Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
[email protected]

Centric Bank Promotes Kimberly L. Turner to Executive Vice President Chief Risk Officer

PR Newswire

HARRISBURG, Pa., April 9, 2021 /PRNewswire/ — Kimberly L. Turner has been promoted to Executive Vice President Chief Risk Officer at Centric Bank, effective immediately, announced Patricia (Patti) A. Husic, President & CEO of Centric Bank and its holding company, Centric Financial Corporation (OTC: CFCX).

“I am pleased to promote Kimberly for her leadership in enhancing Centric Bank’s compliance management systems, but also for setting the framework within compliance and risk to scale us as we continue our growth into a larger financial institution,” says Husic. “The responsible growth of our bank in service to our customers is always top of mind for Kimberly. Her leadership helped propel our female executive team to a three-time Most Powerful Women in Banking Top Team award from American Banker.”

“Being a member of the Centric Bank team only gets more rewarding,” says Turner, who has been an executive at the bank since 2019. “I joined Centric because of their inclusive culture, strong commitment to investing in the communities they call home, and ‘how can we make this happen’ mindset. Our collective response to COVID-19 provided an immediate financial lifeline to our customers and demonstrates how far we’re willing to go for our business community and each other.”

Recruited as the first director of risk management for New York City Energy Efficiency Corporation, a mission-based funder of energy efficiency projects for buildings, Turner established credit decision processes and loan product guidelines and developed underwriting guidelines for small businesses and contractors. She also boasts a 32-year career for banks and financial services firms with a focus on credit, risk, operations, and capital markets serving JP Morgan Chase, Christopher Street Financial, Ernst & Young, LLP, BT Securities Corporation, and Metro Bank.

A lifelong learner, Turner earned her Juris Doctorate from Fordham University School of Law, New York, New York; student clerked in her final year of law school with the Honorable Tina Brozman, Chief Judge of the U.S. Bankruptcy Court, S.D.N.Y; received her MBA in Finance/Accounting from UCLA, Anderson School of Management, Los Angeles, California; and earned a Bachelor of Arts in Psychology from Duke University, Durham, North Carolina.

She is a member of the Association of the Bar of the City of New York and a Licensed Attorney in New York State.

ABOUT CENTRIC FINANCIAL CORPORATION AND CENTRIC BANK
An American Banker 2020, 2019, and 2018 Best Banks to Work For, three-time American Banker Most Powerful Women in Banking Top Team, three-time Best Places to Work, and Top 50 Fastest-Growing Companies for seven years, Centric Bank is headquartered in south central Pennsylvania with assets of $1.1 billion and remains a leader in organic loan growth. A locally owned, locally loaned community bank, Centric Bank provides highly competitive and pro-growth financial services to businesses, professionals, individuals, families, and to the health care and dental industries with the Doctor Centric Bank Division. Centric Bank was named one of the Top 200 Community Banks in the U.S. in 2019 and 2020.

Founded in 2007, Pennsylvania-based Centric Bank has financial centers located in Harrisburg, Hershey, Mechanicsburg, Camp Hill, Doylestown, Devon, and Lancaster, as well as a loan production office in Devon and an Operations and Executive Office campus in Hampden Township, Cumberland County. To learn more about Centric Bank, call 717.657.7727 or visit CentricBank.com. Connect with them on TwitterFacebookLinkedIn, and Instagram.

Centric Financial Corporation is traded over the counter (OTC-Pink) with the ticker symbol CFCX.

Contact:
Anne Deeter Gallaher

Tel. 717.580.4856
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/centric-bank-promotes-kimberly-l-turner-to-executive-vice-president-chief-risk-officer-301265987.html

SOURCE Centric Bank

Vertical Capital Income Fund (VCIF) Declares April Distribution

PR Newswire

DALLAS, April 9, 2021 /PRNewswire/ — Vertical Capital Income Fund (NYSE: VCIF) today announced a distribution of $0.0788 per share pursuant to the Fund’s managed distribution plan (the “Plan”), payable as follows:

Declaration – 4/9/2021

Ex-Date – 4/19/2021

Record Date – 4/20/2021

Payable – 4/30/2021

Pursuant to the Plan, the Fund pays a minimum monthly distribution to shareholders at a stated annual rate as a percentage of the 3-month average net asset value (“NAV”) of the Fund’s shares prior to the month of distribution.  The distribution is calculated as 8% of the previous three-month average NAV, divided by 12.  The primary purpose of the Plan is to provide investors with consistent, but not guaranteed, periodic distributions from the Fund, regardless of when or whether income is earned or capital gains are realized.  Distributions under the Plan may consist of (i) net investment income, (ii) net realized short-term capital gains, (iii) net realized long-term capital gains and, to the extent necessary, (iv) return of capital (or other capital sources). With each distribution that does not consist solely of net investment income, the Fund will issue a notice to shareholders and an accompanying press release that will provide detailed information regarding the amount and composition of the distribution, as well as certain other related information. The Fund expects to issue any such notice and press release on or about the distribution payment date.

The Fund had approximately $2.9 million in cash as of March 31, 2021.  Approximately $9.43 million was committed as of the same date in the acquisition pipeline to loans that have already been awarded to the Fund and were either in due diligence or through due diligence and awaiting closing.  Pending acquisitions are subject to various closing conditions, and the Fund cannot guarantee that those acquisitions will close. 

A new monthly net asset value per share of $11.70 was produced on March 31, 2021.  For information on the Fund’s current net asset value per share, please visit the Fund’s website at vertical-incomefund.com.

The Plan will be subject to periodic review by the Board, and the Board may amend the terms of the Plan including amending the annual rate of payment or may terminate the Plan at any time without prior notice to the Fund’s shareholders.  The Fund’s distribution rate may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors.  There can be no assurance that an unanticipated change in market conditions or other unforeseen factors will not result in a change in the Fund’s distribution rate at a future time.  The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s shares.  The public health crises caused by the COVID-19 outbreak may exacerbate other pre-existing political, social and economic risks to which the Fund is exposed.  The duration of the COVID-19 outbreak and its effects cannot be determined with certainty.  In order to comply with the requirements of Section 19 of the Investment Company Act of 1940, and an exemptive order received by the Fund from the Securities and Exchange Commission, the Fund will provide its shareholders of record on each distribution date with a 19(a) Notice and issue an accompanying press release disclosing the sources of its distribution payment when a distribution includes anything other than net investment income.  This information will be forthcoming later this month.

The amounts and sources of distributions reported in 19(a) Notices are only estimates and are not provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its full fiscal year and may be subject to changes based on tax regulations. The Fund will send shareholders a Form 1099-DIV for the calendar year that will tell them how to report these distributions for federal income tax purposes. Information on the Fund’s 19(a) Notices, if any, can be found at www.vertical-incomefund.com. The final determination of the source and tax characteristics of all distributions in 2021 will be made after the end of the year.


Shares of closed-end funds often trade at a discount from their net asset value. The market price of Fund shares may vary from net asset value based on factors affecting the supply and demand for shares, such as Fund distribution rates relative to similar investments, investors’ expectations for future distribution changes, the clarity of the Fund’s investment strategy and future return expectations, and investors’ confidence in the underlying markets in which the Fund invests. Fund shares are subject to investment risk, including possible loss of principal invested. No Fund is a complete investment program and you may lose money investing in a Fund. An investment in the Fund may not be appropriate for all investors. Before investing, prospective investors should consider carefully the Fund’s investment objective, risks, charges and expenses.  For further details, please visit Vertical Capital Income Fund’s website at vertical-incomefund.com.

This release contains forward-looking statements relating to the business and financial outlook of Vertical Capital Income Fund that are based on the Fund’s current expectations, estimates, forecasts and projections and are not guarantees of future performance. There is no assurance that the Fund will achieve its investment objective. Actual results may differ materially from those expressed in these forward-looking statements, and you should not place undue reliance on any such statements. A number of important factors could cause actual results to differ materially from the forward-looking statements contained in this release.

About Vertical Capital Income Fund

Vertical Capital Income Fund is an NYSE listed closed-end fund that primarily invests in residential whole mortgage loans and residential whole loans secured by deeds of trust.  The investment objective of the Fund is to seek income.

About Oakline Advisors, LLC

Oakline Advisors, LLC is the adviser to Vertical Capital Income Fund.  Founded in 2013, Oakline Advisors, LLC is an SEC-registered investment adviser that specializes in the residential whole loan market. It is a wholly owned subsidiary of Dallas, TX-based Behringer.  Since its inception in 1989, Behringer, together with its affiliates, has raised equity of more than $6 billion in assets through public and private fund structures.  For more information about Oakline and Behringer please visit their respective websites at oaklineadvisors.com and behringerinvestments.com. 

Fund shares are identified by CUSIP 92535C104

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vertical-capital-income-fund-vcif-declares-april-distribution-301265986.html

SOURCE Vertical Capital Income Fund

Century Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Century Bancorp, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CNBKA

Century Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Century Bancorp, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CNBKA

NEW YORK–(BUSINESS WIRE)–
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Century Bancorp, Inc. (NASDAQ: CNBKA) to Eastern Bankshares, Inc. for $115.28 in cash per share is fair to Century shareholders.

Halper Sadeh encourages Century shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

The investigation concerns whether Century and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Century shareholders; (2) determine whether Eastern Bankshares is underpaying for Century; and (3) disclose all material information necessary for Century shareholders to adequately assess and value the merger consideration. On behalf of Century shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Century shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Halper Sadeh LLP

Daniel Sadeh, Esq.

Zachary Halper, Esq.

(212) 763-0060

[email protected]

[email protected]

https://www.halpersadeh.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PR Newswire

LOS ANGELES, April 9, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. (“Aquestive” or “the Company”) (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between December 2, 2019 and September 25, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before April 30, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Aquestive included data in its New Drug Application (“NDA”) submission for Libervant Buccal Film for the management of seizure clusters (“Libervant”) that showed a suboptimal drug exposure level for certain weight groups. This inappropriate data lowered the likelihood of the NDA achieving approval. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Aquestive, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com 
Office: 310-301-3335
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/upcoming-deadline-reminder-the-schall-law-firm-reminds-investors-of-class-action-lawsuit-against-aquestive-therapeutics-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301265948.html

SOURCE The Schall Law Firm